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In earlier papers  (1, 2) it was shown that a  substance, helenine, derived from 
Penicillium funiculosum,  possessed  activity  against  Semliki  Forest  virus  and 
Columbia  SK encephalomyelitis  virus  infections  in  mice  provided  treatment 
was  instituted  within  a  few  hours  following  infection.  The  substance  also 
proved to be active against poliomyelitis  virus infections in monkeys (3)  and 
Eastern  equine  encephalomyelitis  virus  infections  in  mice  (4).  Evidence  has 
been presented that, chemically, helenine is a ribonucleoprotein (5). 
The exact mechanism by which helenine exerted a favorable effect against the vari- 
ous virus infections for which it was found active was not established, but in a paper 
published in 1953 (6) a possible mechanism by which it might act was discussed.  This 
was based on the observation, made in study of its activity against Semliki  Forest and 
SK Columbia viruses, that its effect plateaued, in that beyond a certain level increas- 
ing the dose of helenine did not improve its antiviral effectiveness.  It was concluded 
that "the 'plateauing' would suggest that helenine acts only indirectly through some 
antiviral function of the host itself.  The fact that very large doses or repeated doses 
frequently do not improve the therapeutic result obtained with smaller, optimal doses 
of helenine can perhaps be best explained on the basis of a  'triggering' function for 
helenine--a heavy pull on the trigger of a gun does not fire it any more completely or 
powerfully than does a small but adequate pull" (6). 
Also in the same studies, the observation was made that animals saved by treatment 
with helenine were frequently not immune to subsequent challenge with the virus from 
which  they had  been spared.  From  such findings,  it was concluded  that  "helenine 
therapy against minimal doses of virus exerts its effect,  directly or indirectly, on the 
virus, destroying not only its infectivity, but its antigenicity as well." An alternative 
speculation, resulting from comparison with the action of viral antibody, was that this 
effect of helenine therapy took place at "a stage before the developing virus has ac- 
quired the capacity to elicit an immune response." 
One concept of the mechanism of antiviral  activity of helenine put forward 
in  our  original  publication  was  that  it  possibly  exerted  its  effect  indirectly 
through triggering or inducing the host itself to produce a  substance that was 
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transiently effective  in preventing virus  replication. Furthermore,  this  sub- 
stance, whatever it was, either interfered with the acquisition of viral immunity 
or acted at a stage in virus replication prior to the time that immunizing  antigen 
was produced.  This concept of  the  possible mechanism of helenine antiviral 
activity was formulated during work carried out between 1946 and 1952  at a 
time when our knowledge of the mechanisms of virus replication and of inter- 
ference with viral activity was not as advanced as it is today. Because so much 
new knowledge concerning those phases of virus activity seemingly implicated 
in the  earlier studies has  emerged  since publication of  the  helenine work  in 
1953,  it has seemed worthwhile to  reopen these  studies, and to  consider the 
findings in the light of our newer virological knowledge. 
The  findings to  be  outlined in the  present paper  support  and extend the 
concept presented earlier that the antiviral activit  7  of helenine results not from 
direct action of helenine upon the virus itself but rather through an antiviral 
substance that it induces the treated host to elaborate. The findings further- 
more  extend the  earlier evidence that  the  sparing effect  of helenine in viral 
infections treated by it is effected without the induction of viral immunity. 
Materials 
Mice.--The Rockefeller University strain of Swiss mice, free of known specific pathogens, 
were used in the present work. They were ordinarily about 4 wk of age at the outset of in- 
dividual experiments. 
Virus.--The Semliki Forest virus used was the same strain as that employed in our earlier 
experiments (2) and was initially  isolated by Smithburn and Haddow (7). It is lethally patho- 
genic for our mice in high titer when administered either subcutaneously or intraperitoneally. 
In the present experiments, infections were induced by the subcutaneous inoculation, under 
the loose skin of the back, of 0.5 ce of a dilution of virus containing from 10 to 1000 times 
the amount that regularly killed all untreated control animals. This ordinarily amounted to a 
10  -~ to 10  -8 dilution of infected mouse brain suspended in veal infusion broth pH 7.4. Pools 
of brains from about 15 intracerebrally infected mice, harvested when some were dead and 
the remainder showed characteristic signs of infection, were prepared in 10% suspension in 
broth and divided among a number of screw-capped vials for storage frozen under CO2 until 
ready for use. Kept in this way, the virus retained an adequate potency and a single batch was 
sufficient for about 6 months of experimental work. Dilution of the virus suspension to the 
concentration desired in an individual experiment was made in broth just prior to use and the 
diluted virus was kept in an ice bath during the time of its administration. 
ltdenine.--The heleuine preparations used were prepared essentially as described for earlier 
work with Columbia SK encephalomyelitis virus (1). The important features of this prepara- 
tion were as follows. 
The mold, Penicillium funiculosum,  was grown in stationary cultures on the surface of a 
medium previously described (1) in 32 oz Blake bottles. Each bottle contained 120 cc of me- 
dium and, after inoculation with the mold spores, was placed flat on its side and incubated 
undisturbed at room temperature  (-4-26°C) for from 6 to 10 days. By the end of this time, a 
heavy fleshy pellicle of surface growth had taken place. The pellicles, together with remaining 
culture fluid, were poured onto a double layer of surgical gauze in a large falter funnel and the 
retained pellicles were squeezed almost free of fluid by manual twisting of the gauze in which 
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to contain some helenine activity, this was of such a low order that in the present experiments 
it was discarded and only the pellieles were used as a source of helenine. 
The pellicles were placed in a Waring Blendor and ground for about 4 rain,  adding 10 to 
15 cc of phosphate-buffered saline (pH 7.0),  containing 0.005  ~  magnesium sulfate, for each 
pellich ground. The resulting gruel-like suspension  was then centrifuged at 2000 m,~ at 5°C 
for 30 rain in an International refrigerated centrifuge. The supernatant containing most of the 
helenine activity was decanted for further processing.  It was measured and an equal volume 
of chilled acetone was added to it with stirring. A copious,  gummy, sticky precipitate contain- 
ing all of the antiviral activity resulted. The precipitate, part of which floated, was collected 
by skimming and by centrifugation at 2000 m,~s at 5°C for 30 rain. The clear supernatant was 
decanted and discarded and the brown amorphous gummy precipitate was scraped from the 
bottom and sides of the centrifuge bottles with a spatula using small amounts of phosphate- 
buffered saline containing 0.005 ~s magnesium sulfate to facilitate its removal. Although the 
precipitate would eventually all suspend  or dissolve in the buffered saline by triturating it 
with a spatula in small amounts of fluid, the process of dissolving it could be facilitated by 
homogenizing the precipitate with the desired amount of solvent for about 1 min in a Waring 
Blendor. Ordinarily, in order to achieve a 2- or 3-fold concentration in helenine activity, the 
precipitate was taken up in a volume of buffered saline amounting to one-hail or one-third of 
the volume of fluid from which it had originally been precipitated by acetone. The resulting 
concentrated solution of the acetone precipitate was a  brown turbid fluid high in helenine 
antiviral activity. This could be clarified  without significant loss of activity by slow freezing 
and thawing. In practice, the turbid solution containing helenine was frozen overnight in a 
mechanical freezer at about  -  15°C. It was subsequently placed in an incubator at 37°C and 
thawed without agitation.  A  clear amber fluid containing a  flocculent precipitate resulted. 
This was centrifuged at 2000 Rr~s at 5°C for 30 min. The clear or slightly opalescent amber- 
colored supernatant which contained essentially all of the helenine activity was saved and the 
amorphous precipitate was discarded. It is this clear solution, prepared as just described, that 
has been used as helenine in the present experiments. 
Such solutions of helenine are stable, so far as antiviral activity is concerned, for periods of 
at least as long as 3 months, if stored frozen in screw-capped vials in a mechanical freezer at 
about  --15°C. In practice, we ordinarily distribute each freshly prepared batch of helenine 
in 1~ oz vials to be stored frozen until needed for use.  For reasons that are not presently ap- 
parent, freezing at the temperature of solid COs, it has been found, is not a satisfactory method 
for preserving the full activity of helenine. This is contrary to a statement made earlier (6). 
Methods of Te~ts 
In previous work (1, 2), study of the effectiveness of helenine in viral infections was 
limited largely to tests of its capacity to act therapeutically and little or no considera- 
tion was given to its ability prophylactically to modify viral activity. In view of the 
fact that earlier work had indicated that the activity of helenine might result from its 
stimulation of the host to produce an antiviral material,  it seemed possible that  its 
mechanism of action might be more dearly defined if its prophylactic effectiveness were 
to be studied. The present experiments deal largely with the prophylactic activity of 
helenine, its action when given prior to the administration  of virus. In these experi- 
ments,  helenine has  been  routinely  injected intraperitoneally  and  the  virus by  the 
subcutaneous route. In each experiment, the animals have been kept under observation 
for 14 days since we know from experience that all deaths from Semliki Forest virus 
infection will occur within that interval. At the end of this period of observation, the 
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for the acquisition of immunity by challenge with the same dosage of virus that they 
had previously survived. 
From the standpoint of tabulating the results, the findings with helenine have been 
complicated by their variability. In those experiments in which helenine was given at 
a time to achieve an optimal effect, it has seemed best to record the results on the basis 
of the actual number of survivors. However, in those experiments in which the timing 
of the administration  of helenine was less favorable and in which only prolongation of 
survival time, without survivors, was achieved, some other means of recording results 
had to be resorted to. A comparison of the average survival times, in days, of groups of 
treated animals, with the average survival time of untreated  control animals, was 
TABLE  I 
Prophylactic Effect of Helenine Prepared  from Cultures  of Various Colony Isolates of Penicillium 
funiculosum and Failure of Surviving Mice to  Devdop Immunity 
Helenine  from culture  No.* 
BC 17-5 
R  5-4 
G 28-4 
BC 64-4 
R 5-5 
Controls, average days survived =  3.8 
Initial  infection  with Semliki  Forest 
virus subcutaneously 
Survival index  Survivors 
3.7  39/39§ 
3.1  11/15 
3.3  5/7 
3.7  7/7 
3.6  6/7 
0/18 
Challenge infection 
with Semliki  Forest 
virus subcutaneously:~ 
Survivors 
1/39 
0/11 
1/5 
0/7 
1/6 
* Administered intraperitoneally  24 hr before subcutaneous inoculation with  virus. 
:~ Surviving mice challenged 2 wk after initial infection with same dose of virus. 
§  Surviving mice 
No. of mice in group 
achieved by dividing the value for the treated groups by the corresponding value for 
the control group. The quotient of this division  is a value that enables estimation of the 
therapeutic efficacy of a substance under test, and will be referred to as the survival 
index (SI). In the present paper, in appraising the  antiviral efficacy of helenine, the 
results will be recorded both on the basis of the actual number of survivors as well as 
the survival index. 
Mice that survived their initial infection with Semliki Forest virus for 14 days and 
that were then challenged to test for the acquisition of immunity were  injected sub- 
cutaneously with the same dose of virus they had previously survived. Since, as will 
be shown later, mice almost never withstood rechallenge, the results will be recorded 
only on the basis of survivors. 
Prophylactic Effect of Helenine against Semliki Forest Virus 
Several samples of helenine prepared from cultures of P. funiculosum derived 
from individual colony isolates of the mold were tested for  their capacity to 
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virus infection by 24 hr. As shown by the results given in Table I, helenine saved 
68 out of the 75 mice, to which it was given prophylactically, from a dose of 
Semliki Forest virus that killed all of 18 control mice in an average of just under 
4 days. Of the 68 mice saved by helenine, only 3 survived infection 2 wk later 
TABLE  II 
Prophylactic, Effectiveness of ttdeni.e against Semlik¢ Forest  Virus Infection in Mice 
Time of intraperitoneal administration of 
helenine 
4 days before infection 
1 day  "  " 
12 hr  "  " 
6  "  "  " 
1  gC  t~  Ct 
1 hr after infection 
4  "  ,t  ,, 
12  "  "  " 
18  "  "  " 
24  "  "  " 
Initial infection with Semliki Forest 
virus subcutaneously 
Survival index 
1.3 
2.2 
4.0 
3.8 
3.8 
3.3 
2.1 
1.8 
1.7 
1.8 
1.5 
1.4 
1.6 
1.1 
1.2 
1.1 
1.1 
Survivors 
1/27~ 
9/25 
25/27 
25/29 
25/29 
20/29 
1/12 
0/22 
o/12 
1/15 
o/15 
o/12 
1/lo 
0/7 
o/7 
o/7 
0/7 
Controls, average days survived  ffi  3.4  0/39 
Challenge infection 
with Semliki 
Forest virus 
subcutaneously* 
Survivors 
0/1 
0/7 
0/22 
O/25 
0/25 
0/20 
o/1 
1/1 
1/1 
* Surviving mice challenged 2 wk after initial infection with same dose of virus. 
:~  Surviving mice 
No. of mice in group 
when inoculated with the same dose of virus from which they had initially been 
spared  by  helenine.  This  experiment  demonstrated  that  helenine  exerts  a 
marked prophylactic effect against Semliki Forest virus infection and that the 
mechanism by which it exerts its antiviral activity is one which achieves its 
effect before viral immunity is acquired. 
Influence of Time of Administration on Antiviral Effectiveness of 
ttelenine 
In order to determine the period  of time preceding  infection  during which 
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virus, an experiment in which it was administered at various periods before and 
after virus infection was conducted. The results are recorded in Table II. 
As shown by the findings outlined in this table, helenine exerts very little 
antiviral effect when a period of 4 days elapses between its administration and 
virus infection. The animals in this group survived somewhat longer than the 
untreated controls but all except one out of the  27 in the group succumbed. 
When 3  days intervened between helenine administration and infection with 
virus,  the  treated animals lived on an  average of over twice as long as  the 
controls and 9 out of the 25 in the group survived. It was apparent from this 
result that considerable antiviral effect persisted for at least 3 days after helenine 
administration. Helenine administered 2 days, 1 day, and 12 hr prior to virus 
infection exerted  a  maximal  antiviral  effect and  most  of  the  treated  mice 
survived. So far as could be told from these results, the helenine effect persisted 
in its full strength for a  period extending between 12 and 48 hr after its ad- 
ministration. This constituted a plateau of full effectiveness of approximately 
36 hr duration beginning 12 hr after administration. 
Helenine given 6 hr before virus still exerted a rather marked antiviral effect 
as  evidenced by the survival of about two-thirds  of the mice in  this group. 
However its effectiveness diminished rapidly after this and when it preceded 
infection by only 3 hr, it no longer saved the lives of most of the mice in the 
group though it still doubled their survival time. Among the mice treated with 
helenine at intervals from 2 hr before infection to 4  hr after infection, there 
were essentially no survivors although all groups showed a significant increase 
in survival time as compared with the untreated controls. Helenine given 6 hr 
or longer after infection was completely without antiviral effect in the present 
experiment. It should perhaps be pointed out that the dose of Semliki Forest 
virus used in testing the antiviral efficacy of helenine in this experiment was a 
particularly potent one as evidenced by its killing all of the 39 control mice in 
an average of 3.4 days. Had the infectivity test been a less rigorous one, there 
would undoubtedly have been animals surviving in some of those groups which 
in  the  present  experiment  exhibited  only  prolongation  of  life.  Even  with 
this relatively severe infectivity test, however, the results shown in Table II 
indicate clearly that  a  certain rather definite period  of time must  intervene 
after helenine administration for the development of effective antiviral action. 
The indication is strongly apparent from these results that helenine itself is not 
the substance directly responsible for the antiviral effect under study. Rather 
the ultimate material responsible would appear to be something generated by 
the host itself which reaches full effectiveness between 6 and 12 hr after helenine 
administration and then persists for about 36 hr.  This material,  whatever its 
nature may be,  begins  to decrease sometime between 2 and 3  days after its 
induction by helenine and has largely disappeared by 4 days. 
As in the earlier experiment, all of the survivors in the present experiment 
that had received helenine prophylactically succumbed when later challenged RICHARD E. SHOPE  219 
on the 14th day with a dose of virus from which they had been initially spared. 
Both of the 2 mice that survived from among the groups treated with helenine 
after infection survived the challenge dose of virus. This observation is probably 
of doubtful significance since experience with larger  numbers of animals sur- 
viving in similar experiments has indicated that animals saved by helenine are 
usually  still  fully susceptible  to  virus  infection regardless  of  whether  the 
helenine  responsible  for  sparing  them  initially was  administered before  or 
shortly after virus infection. 
The  orientation of the time of effectiveness of helenine  with the  time of 
administration of virus, as has been done, does not, in all likelihood, accurately 
represent  the true period  of time required  for the induction of the antiviral 
substance  by the host because it does not take into account the exact point in 
the viral infection cycle at which the material acts.  Study of the time of first 
appearance  of detectable Semliki Forest virus in various organs of mice infected 
subcutaneously with a dose of virus the same as that ordinarily employed in 
the helenine experiments has shown that a period of between 7 and 9 hr elapses 
between  inoculation and  the  first  appearance  of detectable  virus.  In  such 
experiments,  approximately 5%  tissue  suspensions  of  thymus,  lung,  liver, 
spleen, kidney, and brain prepared from pairs of mice killed 1, 2, 3, 4, 5, 7, 9, 
10, 11, 13, and 15 hr after subcutaneous  infection were tested for the presence 
of virus by mouse inoculation.  No virus was detectable by this procedure  for 
the first  7 hr  after inoculation.  At  the  9th  hr  after inoculation,  virus  was 
present, in small amounts as judged by the prolonged survival of mice receiving 
the organ suspensions, in the lungs, liver, and spleen, but not in the thymus, 
kidney, or brains.  From the 10th hr onward,  virus was present in all organs 
tested as well as in the brain. 
Assuming from these findings that virus given subcutaneously,  in the dosage 
under study, has gone through one complete  replicative  cycle sometime  be- 
tween 7 and 9 hr after administration and that mice saved after this period 
should therefore be immune to subsequent  infection with the virus, it must be 
concluded, since helenine-spared mice are ordinarily not immune, that helenine 
acts at a point in viral replication sometime prior to the 9th hr postinoculation. 
The mechanism through which  the antiviral substance  induced in mice  by 
helenine might act to interfere with the development of virus and the relation- 
ship of this point of action to the timing of the period of effectiveness of helenine 
will be discussed later. 
Attempted Exhaustion  of the Helenine Effect 
With the acquisition of evidence that helenine exerted its effect by inducing 
the host to which it was administered to produce  an antiviral substance,  it 
seemed worthwhile to try to determine whether this capacity of the host could 
be exhausted by repeated injections of helenine. 
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the previous one just when the full effectiveness of the preceding helenine injection, to judge 
from the findings recorded in Table II, should be near its peak or beginning to wane. In an 
initial  experiment, individual groups of mice were given from 1 to 7 injections of helenine intra- 
peritoneally at these intervals and the last injection in each instance was administered 24 hr 
before the animals were inoculated with Semliki Forest virus subcutaneously at a 10  -s dilution 
of infected mouse brain. 
The results of this first experiment were irregular in that they failed to yield 
an end point indicating complete exhaustion of the capacity of the host to react 
TABLE III 
An Attempt  to Exhaust the Hdenine Effect by Multiple  Repeated Injections 
Helenine intraperitoneally at 
2- or 3-day intervals 
Infection with Semliki  Forest virus  subcutaneously 
Dilutions  of infected  mouse brain  injected  in 0.5 cc dosage 
10  -s  10 -~ 
No. of injections*  Survivors  Survivors 
3/8t 
4/8 
2/7 
2/7 
3/7 
4/6 
0/14 
0/14 
3/13 
5/7  12/14 
Controls, untreated  0/7  0/15 
* Last injection of helenine in each group 24 hr before infection with virus. 
:~  Surviving mice 
No. of mice in group 
favorably to a prophylactic injection of helenine given 24 hr prior to infection. 
As shown in the second column of Table III, a  few of the mice that had had 
from 2 to 6 injections of helenine preceding the last prophylactic dose withstood 
a  10  -s dilution of virus. This indicated that,  even though multiple preceding 
injections of helenine may have diminished the ability of certain of the mice to 
respond to the final injection of helenine, some remained capable of responding 
sufficiently to  protect  them from  a  fatal  outcome with  the  dilution of virus 
employed  to  challenge  them.  Since  it  seemed  possible  that  a  stiffer  virus 
challenge in the experiment might have resulted in a  more definitive demon- 
stration of exhaustion of the capacity to respond to helenine, a  second experi- 
ment was conducted with the view in mind of challenging these animals with a 
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In this second experiment, one group of animals received 9, a  second group 7, and a  third 
group 5, injections of helenine spaced at 2- or 3-day intervals, and in each group the final injec- 
tion of helenine was administered 24 hr before infection. A fourth group of mice received only a 
single injection of helenine 24 hr before infection. Virus challenge in this experiment was with a 
10  -7 dilution of infected mouse brain, a dose of virus ten times greater than had been employed 
in the first experiment. 
As shown in the third column of Table III, all of the mice in the groups re- 
ceiving either 6 or 8 injections prior to the final prophylactic dose of helenine 
died when challenged with the 10  -7 dilution of virus. In like manner, 10 of the 
13 mice in  the  group  receiving four injections of helenine prior to the  final 
TABLE  IV 
A n Attempt to Demonstrate the Acquisition of Immunity to the Hdenine Effect 
Challenge infection 
Helenine intraperitoneally  Initial infection with Sernliki Forest  with Semliki 
virus subcutaneously  Forest virus 
subcutaneously* 
No. of  injections  Interval before infection  Survival index  Survivors  Survivors 
1  24 hr  2.5  7/7~  0/7 
3  2, 3, and 4 wk  0.92  0/14 
4  2, 3, and 4 wk and 24 hr  2.41  12/13  0/12 
Controls, average days survived  =  5.6  0/7 
* Surviving mice challenged 2 wk after initial infection with same dose of virus. 
Surviving mice 
No. of mice in group 
prophylactic dose also succumbed. In contrast, only 2 of the  14 mice in the 
group receiving but a single injection of helenine 24 hr before inoculation with 
virus  died.  All of  15  control mice in  the  experiment succumbed.  As  in  the 
preceding experiments, surviving mice developed no immunity as a  result of 
their initial exposure to virus and were susceptible when rechallenged  14 days 
later with the same dose of virus that they had earlier withstood. 
It seems clear that the results recorded in Table III indicate that the pro- 
longed administration of helenine at 2- or 3-day intervals markedly weakens, 
and in some instances exhausts, the capacity of the mouse to respond favorably 
to a  prophylactic dose of helenine given 24 hr before virus infection. These 
findings further support the view that  helenine does not act directly on the 
virus but rather exerts its antiviral effect by inducing the host to elaborate a 
material which is responsible for the antiviral effect. This material, whatever its 
character, seemingly does not exist in the host in unlimited amount as evidenced 
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stimulated  by  helenine  injections  spaced  at  intervals  favorable  to  its  con- 
tinuous elaboration. 
Attempted Demonstration of Immunity to the Helenine Effect 
In order to test the possibility that the anfiviral material induced in mice might be 
antigenic,  two groups of mice were given three intraperitoneal injections  of helenine 
spaced  at weekly  intervals 2,  3,  and 4 wk  prior to infection  subcutaneously with 
Semliki Forest virus. One of these groups, together with another group of animals, were 
injected intraperitoneally with helenine 24 hr before inoculation with virus. 
As shown in Table IV, the mice that had had three injections of helenine at 
weekly  intervals  and  then  a  prophylactic  injection  24  hr  before  infection 
reacted to the infection just as did the group that received only the prophylactic 
injection of helenine and 12 of the 13 mice in this group survived. All 14 of the 
mice in the group that had had three weekly injections of helenine terminated 
2  wk prior  to infection and no prophylactic dose, died in roughly the  same 
average number of days as did the controls. The outcome of this experiment 
indicated  that  mice in  which  the  antiviral  substance  had  been induced  by 
helenine  three  times  at  weekly  intervals  did  not  become  refractory to  its 
effect as a result of these previous exposures. The indication was that the anti- 
viral substance, whatever its character, was not antigenic for the host in which 
it was induced under the conditions of this experiment. 
DISCUSSION 
The findings in the present experiments have supported the tentative con- 
clusions drawn from those of earlier work (6) that the antiviral effect of helenine 
is not due to  a  direct  action of  helenine itself  but rather  results indirectly 
through  the  stimulation  by it  of some  antiviral  function  of the  host  itself. 
Evidence for this conclusion is supplied, so far as the present experiments are 
concerned, by the finding that a  definite period of time must elapse between 
the administration of helenine to a  host and the acquisition by that host of 
full resistance to viral infection. Were the antiviral  effect a  direct action of 
helenine  itself,  it  would  be  anticipated  that  its  greatest  activity  would  be 
expressed within a  short time after administration when the concentration of 
helenine in the host was presumably greatest and that it would then diminish. 
It might perhaps be postulated that the observed lapse of time necessary for 
the host to acquire full protection against a virus, following helenine administra- 
tion, corresponded to the period required for the host to convert, through some 
metabolic process, inactive helenine into a product possessing antiviral activity. 
Such a postulation would be easier to support were it not for the fact that the 
antiviral  activity,  once  established  in  the  host,  persists  in  apparently  full 
effectiveness for at least 36 hr. It would be very difficult to think that a metab- 
olite of helenine would be maintained fully effective for so long. Furthermore, RICHARD E. SHOPE  223 
if the antiviral effect of helenine resulted directly from a  metabolic product 
derived from it, it would be anticipated that a  dose response to it would be 
demonstrable. 
The  simplest and  most  readily supportable  interpretation of  the  findings 
that have been described is that helenine induces the host to produce an anti- 
viral substance and that this induction requires  time to reach its  maximum 
effectiveness. In the case of the virus employed in the present experiments, and 
at the virus dosages studied, the time lapse to assure complete protection  of 
over half the animals, must be approximately 6 hr between helenine administra- 
tion and virus inoculation. The antiviral substance reaches its height, to judge 
from its ability to spare the lives of virus-inoculated mice, in approximately 12 
hr.  It maintains its high level of activity until at least 48  hr after helenine 
administration and then gradually diminishes until by 96 hr it has largely dis- 
appeared. Its maximum activity is thus manifested during a plateau period of 
36 hr between 12 and 48 hr after helenine administration. 
A finding that has been very constant in the experiments described has been 
the failure of mice, that were spared by helenine, to develop immunity. Almost 
uniformly animals  saved  as  a  result  of  helenine  administration have  been 
subsequently fully susceptible  when later  challenged with the same  dose of 
virus from which they had been spared. This observation confirms that made in 
earlier work  (6)  which at the time was interpreted as indicating either that 
helenine therapy acted, directly or indirectly, upon the virus, destroying not 
only its infectivity but its antigenicity as well, or that its effect occurred during 
a stage before the developing virus had acquired the capacity to elicit an immune 
response. Much more is known now than then about virus replication and the 
finding that helenine-spared mice are still susceptible can be definitely invoked 
as evidence that the action of the antiviral substance induced by heleuine occurs 
at a stage in viral nucleic acid replication prior to that in which antigenic viral 
protein is produced. What is not made evident by the present experiments is 
whether the antiviral substance acts very early and prevents penetration of 
virus into cells in which it can develop or later at one of the stages of viral 
nucleic acid replication before antigenic viral protein is produced. 
When one considers the possible sites of action, in the virus replication cycle, 
of the antiviral substance induced by heleuine, it becomes apparent that the 
findings recorded in Table II in this paper should all be increased by from 1 to 
7 hr, depending on the point in the cycle at which this activity expresses itself. 
Since  infective virus  first  becomes  detectable  in  small  amounts in  animals 
inoculated subcutaneously, in about 9 hr after inoculation, it is apparent that 
by this time the virus has gone through at least one complete replicative cycle 
and that mice saved at such time should therefore be immune to later virus 
challenge. Since helenine-spared mice are not immune to subsequent infection, 
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time when a total cycle of virus replication has not yet been completed. Thus, 
if the antiviral substance acted at a point in virus replication just prior to its 
completion, the period of time required for the host to generate fully effective 
viral protection after helenine administration could be as long as  13 hr,  i.e., 
the 7 hr elapsing between virus inoculation and the time just before infective 
virus became first detectable plus the 6 hr, shown from the results in Table II, 
that must elapse between helenine administration and the acquisition by the 
host of near-full viral protection. If, on the other hand, the antiviral  substance 
acts  to prevent virus  penetration  of susceptible  cells,  then its  induction  to 
almost full effectiveness within the host would be expected to be but an hour 
or two longer than the  6 hr indicated by the findings recorded in Table II. 
In  either case,  the  time  required for helenine to induce maximal  protection 
against the fatal infection of mice by Semliki Forest virus should be calculated 
as from 1 to 7 hr longer than that shown in Table II, depending upon the stage 
in viral infection at which  the  helenine-induced antiviral  substance  actually 
exerts its life-sparing effect. In like manner, calculation of the period during 
which its  activity persists at  a  high  level of effectiveness would  have  to be 
altered correspondingly. 
The nature of the helenine-induced antiviral substance cannot be determined 
from the findings reported. Of the known reactions that can be induced in a 
host  to protect it  against  the  deleterious effects of virus infection,  the  best 
studied is the interferon reaction of Isaacs and Lindenmann (8). Interferon is a 
substance elaborated by virus-infected cells which possesses definite chemical 
and physical properties dependent upon the host cell producing it. It modifies 
the cells of the species of host in which it is induced in such a manner as tran- 
siently to preclude the normal developmental cycle or the production of patho- 
logic effect of various  viruses in  these  cells.  Interferon, responsible  for  this 
antiviral effect, is released from the cells producing it in a  fully active form. 
More recently, Isaacs, Cox, and Rotem (9) have found that nucleic acids other 
than those of viral origin can stimulate cells to produce interferon. Also Klein- 
schmidt, Cline, and Murphy (10) have attributed the activity of the antiviral 
agent, statolon, to its capacity to induce interferon production in hosts treated 
with it. This observation is especially pertinent to our own studies with helenine 
because,  though  the  chemical  nature  of  statolon  and  helenine  as  published 
(11, 5)  are quite different, the in vivo activities of the two materials  against 
virus infections are  remarkably similar.  Whether,  as in  the  case of statolon 
(10), the antiviral activity induced by helenine also represents an interferon or 
interferon-like effect is  being  studied  by  Dr.  Michael  Rytel  of  the  Cornell 
University Medical  College,  and  his  findings  will form the  basis  for  a  later 
paper. 
At the time that the initial studies with helenine were carried out, Isaacs and 
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no basis as yet existed for comparison of the two antiviral activities.  Even now 
the technical approaches used in the study of helenine and interferon have been 
so different that there is little basis for comparing  the results  obtained. The 
work with interferon has been done largely in embryonating eggs or cell culture 
and relatively little has been conducted in the intact host. Helenine studies, on 
the other hand, aside from those currently being carried  out by Rytel, have 
dealt almost entirely with the antiviral activity of the substance in the intact 
host.  Strangely  enough,  these  two  approaches  have  resulted  in  divergent 
findings so that aside from the fact that both interferon and helenine interfere 
with the progress  of virus infections,  the remaining  findings have few facets 
that can be accurately compared.  Thus though the period  required  for the 
induction of interferon, as tested in cell culture, by materials administered to 
intact hosts is known, little attention has been paid to the timing of the acquisi- 
tion of full protection against viral infection by the host itself. Also though 
diligent search of the literature has been made, I have been unable to find a 
single record  of any study in which  animals saved  by interferon have been 
subsequently tested for immunity to the same  virus from which  they were 
spared.  Thus, in this respect,  there is no knowing whether interferon, like the 
antiviral substance  induced  by  helenine,  spares  the  lives  of  virus-infected 
animals without their acquisition  of immunity to the virus from which they 
were saved. If the antiviral substance induced by helenine is indeed interferon, 
the prolonged period during which its effect lasts (up to between 48 and 72 hr) 
as compared with the much briefer periods of its known persistence in the blood 
stream following stimulation by virus administration, would suggest its depot 
storage somewhere in the host long after it disappears  from the blood stream. 
It is  because  of this complete  lack of grounds  for comparison  between  the 
known properties  of interferon and the known activities of the helenine-induced 
antiviral  substance  that  experiments  with  helenine,  designed  to  study its 
capacity to induce interferon, have been initiated by Dr. Rytel. 
The finding  that the prophylactic effect of helenine  can be  weakened  or 
exhausted by repeated administration at 2- or 3-day intervals furnishes further 
evidence that the antiviral effect of helenine results not by its direct action on 
the virus but rather indirectly through some material that the injected host is 
induced to elaborate.  This material seemingly either exists preformed in only 
limited amounts or is capable of elaboration by the host in only limited amounts 
under the stimulus of helenine.  Its exhaustion in the experiments  under dis- 
cussion was not accompanied by any evident deleterious effect on the host, for 
the mice,  even  those  that received  as many as nine injections  of helenine, 
appeared lively and grossly normal prior to infection with virus. 
The failure to induce immunity to the antiviral substance, repeatedly induced 
by injections of helenine at weekly intervals, was evidenced by the continued 
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Under the experimental conditions prevailing in the experiments described, the 
antiviral  substance,  whatever its  character,  seemingly was  not antigenic  for 
the host in which it was induced by helenine. This would suggest  that it was 
either not protein in character or if protein, was one native to the host in which 
induced. 
SUMMARY 
1.  Helenine injected intraperitoneally 24 hr prior to a regularly fatal dose of 
Semliki Forest virus saves most of the mice to which it is administered. 
2.  Mice saved by helenine develop no viral immunity and regularly succumb 
when rechallenged 2 wk later with the same dose of virus from which they were 
originally saved. 
3.  The time during which helenine is optimally effective in protecting mice 
from death  by Semliki  Forest virus  covers a  period of approximately 36 hr 
beginning after about 12 hr and extending to 48 hr before virus infection. When 
periods of less than 12 hr, or more than 48 hr, elapse between the time of helenine 
administration  and  virus  inoculation,  its  protective effectiveness diminishes 
progressively. 
4.  Repeated injections of helenine at 2- or 3-day intervals, if continued long 
enough, exhaust the capacity of a  host to respond favorably to helenine ad- 
ministered 24 hr before virus inoculation. 
5.  Helenine injections at intervals of 4, 3, and 2 wk before its administration 
24 hr prior to infection do not decrease the effectiveness of this final dose in 
protecting mice from fatal infection by the virus. 
The experimental results here reported indicate that,  as suggested by the 
findings of earlier work, helenine does not act directly as an antiviral substance, 
but instead exerts its effect through some substance that it induces the host to 
elaborate. The nature of this induced antiviral substance is as yet unknown 
though, to judge from the failure of spared mice to acquire viral immunity, it 
appears to act at a  stage in viral replication prior to that at which antigenic 
viral protein is produced. 
The findings with helenine and those thus far reported for interferon afford 
no factual basis for judging the relationship of the two, if any. 
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